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Both studies on animals and humans suggest the presence of dopamine (DA) receptors in the anterior segment of the eye. Their
role in the dynamics of intraocular pressure (IOP) is not yet clear. DA
2
and DA
3
receptors are mainly located on postganglionic
sympathetic nerve endings. Their stimulation reduces the release of norepinephrine and suppresses the production of aqueous
humor.DA
1
receptors seem to bemore expressed by the ciliary body and the outflowpathway of aqueous humor.The administration
of DA
1
-selective agonists stimulates the production of aqueous humor, increasing IOP, whereas DA
2
- and DA
3
-selective agonists
could reduce IOP and, therefore, the risk to develop a glaucoma (GL). GL is a broad spectrum of eye diseases which have in
common the damage to the optic nerve and the progressive loss of the visual field. Further studies are desirable to clarify the role
of the dopaminergic system and the usefulness of DA
2
and DA
3
agonists in reducing IOP.
1. Introduction
Biological basis of glaucoma (GL) are not yet fully under-
stood, and the factors involved in its progression are not
yet fully identified. The most important risk factor is high
intraocular pressure (IOP), due to the reduction in the
outflow of aqueous humor through the iridocorneal angle
[1, 2]. Other risk factors are aging (in elderly the prevalence of
the disease is higher), family history, African-Caribbean race,
high myopia (>4D), thinner cornea, lens pseudoexfoliation,
low blood pressure (diastolic one in particular), and local
and systemic vascular risk factors (optic disc hemorrhage or
atrophy, vasospasm, etc.) [1–4].
Physiologically, IOP is regulated by a proper balance
between secretion and drainage of aqueous humor. This is
produced by ciliary body’s epithelium into the posterior
chamber from which passively diffuses into the anterior one
through pupil [3–5]. Once in the anterior chamber, about
80% of aqueous humor outflows through the trabecular
meshwork and then in a small vessel called Schlemm’s canal.
Finally, through aqueous veins, it comes out from ocular
bulb by episcleral veins and reaches the bloodstream. The
remaining 20% of aqueous humor flows, independently from
IOP, through the uveoscleral outflow or along nerves and
small ocular vessels [4–7].
High IOP is one of the most important risk factors
involved in GL and is the only one against whom actual
therapies are really effective. Epidemiological studies showed
that the risk of GL increases by 12% for each 1mmHg increase
of IOP [1, 2, 8]. To date, GL is the second leading cause of
blindness in the world [8]. GL can be congenital or acquired.
The further classification in primary open-angle glaucoma
(POAG) and primary angle-closure glaucoma (PACG) con-
cerns the mechanisms that hinders aqueous humor outflow.
In primary GL, the increase of IOP is not associated with
other ocular disorders, while in secondary GL, a recognizable
factor, ocular or nonocular one, alters the outflow of aqueous
humor. In western countries, POAG is more common than
PACG [1, 2, 8].
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Molecular events responsible for GL are still for the
most part unknown. Several molecules are able to regulate
IOP: adrenergic, cholinergic, serotonergic, and dopaminergic
systems are all involved.
Dopamine (DA) is a simple organic chemical in the
catecholamine family released from postganglionic nerve
fibers of the superior cervical dopaminergic ganglion in the
aqueous humor [9–12] and exerts its action by binding to 5
different types of DA receptors (DA
1−5
) which belong to the
superclass of G-proteins coupled receptors.
DA receptors are grouped in two distinct families: DA
1
-
like receptors (which include DA
1
and DA
5
receptors) and
DA
2
-like receptors, like DA
2
, DA
3
, and DA
4
[11–14]. The
main difference between those families of receptors concerns
the action of G-proteins: DA
1
-like receptor has a Gs-protein
whose activation results in an increase of cyclic AMP (cAMP)
mediated by adenylate cyclase [9, 10, 12]. DA
2
-like receptors
are coupled to a Gi-protein which determines, instead,
the inhibition of adenylate cyclase and, consequentially, a
decrease of cAMP (Figure 1).
The aim of this review is to investigate, specifically, the
dopaminergic influence on IOP to evaluate the role of new
hypotensive drugs.
2. Studies on Animals
Early studies of the role of DA in GL on animal models
led to contrasting results. Shannon et al. [15] showed that
DA, administered topically, increases IOP in rabbit eyes,
and haloperidol (DA inverse agonist) can contrast that
action. Green and Elijah [16] noticed, by contrast, that
IOP decreased during parenteral administration of DA,
indicating that a different route of administration of DA
produces different effects on IOP. In 1984, Potter et al.
[17] studied the sequel of topical administration of DA
and its methylated analogs: N-methyl-dopamine (NMDA),
N,N-dimethyl dopamine (DMDA), and N,N-Di-n-propyl
dopamine (DPDA) in eyes of healthy rabbits and of sym-
pathectomized ones. Thus, in normal rabbits, DA, DMDA,
and NMDA induced an increase of IOP unilaterally, while
DPDA induced a bilateral hypotension after unilateral topical
administration.
Furthermore, in sympathectomized rabbits they noted
the following results:
(1) the administration of NMDA and DMDA produced
an exaggerated ocular hypertension, followed by
hypotension;
(2) the hypotensive effects of DPDA registered in normal
rabbits eyes were absent in sympathectomized ones.
In summary, they assessed that DA and its analogues
produce two different effects:
(A) a direct and postjunctional effect, mediated by DA
agonists that bind to DA
1
, 𝛼, and 𝛽 receptors;
(B) an indirect and prejunctional (or “neuronal”) effect,
mediated by DA agonists that bind 𝛼
2
and DA
2
receptors.
Green et al. [9, 16], studying rabbit’s ciliary epithelium
in vitro, observed that DA increases passive permeability
and active secretion of aqueous humor. Both effects could
be inhibited by 𝛼 and 𝛽 antagonists, phentolamine, and
sotalol, respectively, but not by a relatively selective DA
antagonist (butaclamol) [18]. The secretory function of DA
was subsequently confirmed by studies that identified, on
nonpigmented epithelium of the ciliary body of animals
and humans, the phosphoprotein 3󸀠–5󸀠 monophosphate
(DARPP-32) which regulates adenosine andDA systems [19].
Potter et al., however, showed that topical administration
of some ergoline (lergotrile, pergolide) and an ergopeptide
(bromocriptine), both in rabbits and monkeys, decreased
IOP by acting on DA
2
receptors [17, 20, 21]. The action of
DA
2
receptors was further confirmed by a subsequent study
by Potter [12]. He noted a decrease hypotensive effect of
ergoline in eyes of rabbits pretreated with domperidone (a
DA
2
antagonist) and surgical sympathectomy.
In summary:
(1) the decrease of IOP mediated by ergot derivatives is
partly dependent to sympathetic neuronal activity;
(2) probably DA
2
receptors are expressed in the sym-
pathetic ganglion and/or sympathetic postganglionic
nerveendings;
(3) ocular hypotension is just partially due to the inhi-
bition of formation of aqueous humor. To further
confirm that indirect effects are responsible for lower-
ing IOP, Savolainen et al. [22] reported that selective
DA
2
/𝛼
2
agonist like CHF1035 and its metabolite
CHF1024, if instilled in rabbit’s eyes, have similar
effects to brimonidine in lowering IOP, but CHF1035
has a long lasting action too.
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These data suggest the presence of DA receptors in
the anterior segment, but in order to better understand
and investigate their role, it was important to precisely
identify where the structures were present. Many biochem-
ical, immunohistochemical and functional studies have been
performed on animal tissue samples to find DA
1
receptors
localization, but not DA
2
ones. DA
1
receptors are present
on ciliary body epithelium of bovine [11, 19] and on ciliary
processes epithelium of rabbit [9, 15, 18] confirming that their
stimulation causes from one side an increased production of
aqueous humor and, on the other hand, an altered outflow
of it affecting the tone of ciliary muscle. DA
2
receptors main
localization seems to be the postganglionic presynaptic nerve
ending [22].
In addition to the previously mentioned receptors, Chu
et al. showed the involvement of a specific DA receptor, the
DA
3
, responsible for IOP hypotonization in an animal model
of rabbit [23]. Recently, some authors studied the hypotensive
effect of 7-hydroxy-2-dipropilaminotetralina (7OH-DPAT),
themain agonist of DA
3
receptor on rabbit eyes [23], showing
that
(1) IOP lowering effect of 7-OH-DPATwas due in part to
the reduction of the production of aqueous humor;
(2) the nervous site of action of 7-OH-DPAT has been
identified immunohistochemically as the DA
3
recep-
tor of ciliary body and has been associated with the
decrease of hypotensive effects in rabbits deprived of
sympathetic nerve endings;
(3) the inhibition of the hypotensive effect of 7-OH-
DPAT by DA
3
receptor antagonists (U99194A and
UH232) and the deprivation of postganglionic sym-
pathetic endings, together with the immunohisto-
chemical data, showed that the primary site of action
of 7-OH-DPAT is located in the presynaptic postgan-
glionic nerve endings of the ciliary body of rabbit
eyes.
A similar study, conducted on mice, was performed by
Bucolo et al. [14]. The authors observed that topical appli-
cation of 7-OH-DPAT, 𝛼 DA
3
preferring receptor against,
significantly decreased in wild-type (WT) mice both in
an ocular normotensive group and an ocular hypertensive
steroid-induced group. Instead, there were no changes of IOP
in DA
3
receptor knockout mice. Moreover, genetic analysis
conducted on ocular tissues of WT mice with PCR showed
several genes encoding for all DA receptors but the absence
of the receptor gene in DA
3
KOmice [14].
3. Studies on Humans
The expression of DA
2
receptors in the anterior segment of
the eye in humans has been confirmed by functional data, but
there are no studies which revealed their localization.
Unlike DA
2
receptors, DA
1
have also been identified
in human eyes [19] with biochemical and autoradiographic
techniques using [3H]-SCH-23390, a selective antagonist of
DA
1
receptor. DA
1
receptors were present on uveoscleral
tissue, trabecular meshwork, and ciliary processes [7]. Eleven
eyes, enucleated because of trauma but with no involvement
of the iridocorneal angle, were analyzed. Seven eyes were
treated for GL, while four of them had a normal IOP.
Although the sample size was very small, a higher response,
due to DA
1
receptors, was noticed in eyes with normal IOP
[7].
Mekki et al. demonstrated, in a double-blind study, that
in 8 healthy volunteers without IOP alteration treated with
oral bromocriptine (1.25mg), IOP decreased (compared to
placebo) at 3 and 4 hours after the administration, with no
effects on systemic arterial pressure and on pupil’s diameter
[24, 25]. These results were later confirmed by a study
involving patients suffering from Parkinson’s disease and
POAG. In fact, a decrease in IOP occurred when levodopa
was replaced by bromocriptine per os (2.5mg) [26]. This
drug has effects on the production of prolactin, and Mekki et
al. showed that the eye drops containing bromocriptine can
reduce IOP compared to placebo [24, 25].
In a double-blind, randomized, and prospective study,
IOP was measured in 24 healthy subjects at baseline and 2,
4, and 6 hours after the instillation of topical timolol (0.25%)
and bromocriptine (0.05%). Both bromocriptine and timolol
decreased IOP significantly from baseline with no difference
between them at 2 and 4 h, but, at 6 h, bromocriptine was
more effective than timolol [27].
Al-Sereiti et al. showed that the hypotensive effect of
pergolide (25 micrograms orally) was antagonized by a
pretreatment with oral domperidone (15mg), a DA
2
receptor
low-selective peripheral antagonist [28].
DA
1
receptor agonists were topically administered (DA,
ibopamine, fenoldopam, and 3B90) in a study performed
on 20 patients with POAG [29]. The authors demonstrated
that the increase of IOP after the administration of those
molecules was not inhibited neither by the administration of
haloperidol nor by already known hypotensive drugs. Just the
administration of a selective DA
1
agonist (SCH-23390) was
capable to reduce IOP, confirming that those receptors are
involved in determining IOP.
Karnezis et al. showed that intravenous administration
of angiotensin II, norepinephrine, and fenoldopam increased
IOP in human subjects by the stimulation of DA
1
receptors
[30]. Subsequently, it was confirmed that the stimulation by
fenoldopam could alter the outflow of the aqueous humor
increasing IOP [31].
Among DA
1
receptor agonists, we can also include the
3,4-di-isobutyrrylester of N-methyldopamine, better known
as ibopamine [32, 33]. This widely studied molecule has the
following pharmacological properties:
(1) it increases the production of aqueous humor stim-
ulating DA
1
receptors both in healthy eyes and in
glaucomatous ones;
(2) it is a valid provocative test to study the efficiency
of aqueous humor outflow pathways; in fact, in close
relatives of patients with POAG, the instillation of
ibopamine 2% causes an increase in IOPwhich would
not occur in subjects without familiarity for POAG.
Those data explain that high IOP due to the administra-
tion of ibopamine is not caused by the increased production
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of aqueous humor but by an alteration of the outflow path-
ways [13, 32–34]. Ibopamine induces a cycloplegic mydriasis
not acting on 𝛼 receptors. Moreover, it can be used in
hypotensive syndromes like anterior uveitis or damage of the
ciliary body or after GL filtration surgery [33, 34].
Recently, Virno et al. [35] assessed the effect of ibopamine,
a D1-dopamine agonist, on IOP in offsprings of parents with
POAG as a consequence of outflow structures impairment.
D1-dopaminergic stimulation due to ibopamine increases
IOP as a result of increased production of the aqueous
humor in participants with an impaired outflow. The study
showed that after 2% ibopamine administration, there was
a significant increase in aqueous humor production, both in
glaucomatous and normal eyes.The intraocular hypertensive
response due to ibopamine in normotensive eyes is a sign of
initial outflow impairment and, therefore, a predisposition to
intraocular hypertension and possible GL.
After this overview, we can conclude that the effects of
DA and its analogs on IOP are complex: they can have both
direct effects (postjunctional) and indirect (prejunctional)
ones. The postjunctional effects of DA agonists can stimulate
𝛼, 𝛽, and DA
1
receptors. Similarly, indirect effects neuronal
may be mediated by 𝛼
2
, DA
2
and DA
3
receptors (Figure 2).
In particular, DA
1
agonists seems to increase the production
of aqueous humor with a consequent increase of IOP, while,
DA
2
agonists are responsible of a decrease of IOP (Figure 3).
4. Conclusions
Although several classes of drugs are known to reduce IOP,
just 5 of them are used in clinical practice. It is still necessary
to look for the most powerful (and safer) therapeutic agent
in order to reduce the serious consequences of GL. From
the studies carried out on animals and humans, discussed
previously, we can conclude that DA
2
, and DA
3
agonists
have an important influence on the modulation of IOP,
with significant implications for the management of patients
affected by GL.
Further studies are needed to clarify the role of the
dopaminergic system and the usefulness of DA
2
and DA
3
agonists in lowering IOP.
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